U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C15H23NO2.ClH
Molecular Weight 285.81
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALPRENOLOL HYDROCHLORIDE

SMILES

Cl.CC(C)NCC(O)COC1=CC=CC=C1CC=C

InChI

InChIKey=RRCPAXJDDNWJBI-UHFFFAOYSA-N
InChI=1S/C15H23NO2.ClH/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3;/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3;1H

HIDE SMILES / InChI

Molecular Formula C15H23NO2
Molecular Weight 249.3486
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Alprenolol is a beta adrenoreceptor blocking agent and 5HT1A antagonist, developed by AstraZeneca and now available as generic drug. It is used for treatment of hypertension, angina pectoris due to coronary atherosclerosis and acute myocardial infarction.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
6.93 null [pKi]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TENORMIN
Primary
TENORMIN
Primary
TENORMIN

Cmax

ValueDoseCo-administeredAnalytePopulation
216.9 ng/mL
200 mg single, oral
ALPRENOLOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
67 ng × h/mL
5 mg single, intravenous
ALPRENOLOL plasma
Homo sapiens
706 ng × h/mL
200 mg single, oral
ALPRENOLOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
4 h
200 mg single, oral
ALPRENOLOL plasma
Homo sapiens

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
For treatment of hypertension and angina pectoris the initial dose of TENORMIN is 50 mg given as one tablet. If an optimal response is not achieved, the dosage should be increased to TENORMIN 100 mg given as one tablet a day. In patients with definite or suspected acute myocardial infarction, treatment with TENORMIN I.V. Injection should be initiated as soon as possible after the patient's arrival in the hospital and after eligibility is established. Such treatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. Treatment should begin with the intravenous administration of 5 mg TENORMIN over 5 minutes followed by another 5 mg intravenous injection 10 minutes later.
Route of Administration: Other
In Vitro Use Guide
Binding of alprenolol to beta adrenergic receptors was measured using [3H]CGP 12177 as a radioligand in the ranges of 0.71-3.14 nM, and whole CHO cells, expressing beta1, beta2 and beta3 adrenergic receptors. Alprenolol inhibits binding of log Kd of -7.95, -9.3 and -6.86 for beta1, 2 and 3 respectively.
Substance Class Chemical
Record UNII
2502C2OIRK
Record Status Validated (UNII)
Record Version